Author

Panagiotis Baxevanos

Observed names: P. Baxevanos, P.T. Baxevanos, PANAGIOTIS BAXEVANOS

Institution: 401 General Military Hospital of Athens

Observed institutions: Azienda Ospedaliera di Perugia, 401 General Military Hospital of Athens, NIMTS Hospital, University Hospital of Geneva, St Savas Hospital, Athens Naval & Veterans Hospital

ORCID: 0000-0002-0589-2226

Observed ORCID: 0000-0002-0589-2226

OpenAlex ID: A5004251271

Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?

2018 · Panagiotis Baxevanos, Giannis Mountzios · Annals of Translational Medicine · 83

PDF

Advanced small cell lung cancer (SCLC): new challenges and new expectations

2018 · Nikolaos Tsoukalas, Eleni Aravantinou-Fatorou, et al. · Annals of Translational Medicine · 82

PDF

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

2019 · Giulio Metro, Alfredo Addeo, et al. · Journal of Thoracic Disease · 46

PDF

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

2020 · Alex Friedlaender, Giulio Metro, et al. · Acta Oncologica · 39

PDF

PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.

2019 · Nikolaos Tsoukalas, Maria Kiakou, et al. · PubMed · 39

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

2020 · Giannis Mountzios, Alessandro de Toma, et al. · Clinical Lung Cancer · 31

Advances on systemic treatment for lung neuroendocrine neoplasms

2018 · Nikolaos Tsoukalas, Panagiotis Baxevanos, et al. · Annals of Translational Medicine · 29

PDF

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

2020 · Giulio Metro, Giuseppe Luigi Banna, et al. · Journal of Immunotherapy · 28

Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer.

2017 · Nikolaos Tsoukalas, Ioannis D Kostakis, et al. · PubMed · 10

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

2024 · NIKOLAOS TSOUKALAS, KONSTANTINOS TSAPAKIDIS, et al. · Cancer Diagnosis & Prognosis · 8

PDF

Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.

2020 · Alfredo Addeo, Giulio Metro, et al. · Journal of Clinical Oncology · 4

Engagement of patients with cancer with digital health platforms: An age-based analysis.

2024 · Paris A. Kosmidis, Panagiotis Baxevanos, et al. · Journal of Clinical Oncology · 1

P-223 Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy

2020 · A. Ioannou, S. Demiri, et al. · Annals of Oncology · 1

142TiP SARC-Digital: An obServational, rAndomized, pRospeCtive study of the impact of digital health interventions on symptom and side-effect management in patients with metastatic sarcoma

2024 · S. Kokkali-Zervos, J. Durán Moreno, et al. · ESMO Open

PDF

Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest

2019 · G. Mountzios, D. Signorelli, et al. · Annals of Oncology

P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort

2019 · G. Metro, D. Signorelli, et al. · Journal of Thoracic Oncology

368 Primary breast carcinosarcoma

2019 · N. Tsoukalas, K. Tsapakidis, et al. · International Journal of Gynecological Cancer

PDF

Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy

2019 · A. Ioannou, S. Demiri, et al. · Annals of Oncology

P1.09-35 Clinical Impact of Systematic Inflammation and Histologic Grade in Non Small Cell Lung Carcinoma (NSCLC)

2018 · N. Tsoukalas, C. Giaginis, et al. · Journal of Thoracic Oncology

PDF

P1.09-36 Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)

2018 · N. Tsoukalas, C. Giaginis, et al. · Journal of Thoracic Oncology

Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era

2018 · N.G. Tsoukalas, E. Aravantinou, et al. · Annals of Oncology

Works count: 21

Citation count: 401

H-index: 9

I10-index: 9